Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNTH Dianthus Therapeutics	$17.63 -2.8%	$19.12	$13.37 ▼ $32.27	$566.98M	1.37	262,944 shs	789,409 shs
IPHA Innate Pharma	$1.85 -3.1%	$2.08	$1.29 ▼ $3.51	$170.53M	0.26	187,219 shs	3,484 shs
XERS Xeris Biopharma	$4.70 -0.8%	$4.63	$2.03 ▼ $6.07	$734.99M	0.71	2.02 million shs	4.69 million shs
ZYBT Zhengye Biotechnology	$6.61 -6.2%	$8.71	$3.50 ▼ $14.30	$311.79M	N/A	439,940 shs	268,809 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNTH Dianthus Therapeutics	0.00%	+4.63%	+1.21%	-2.81%	-31.88%
IPHA Innate Pharma	0.00%	+2.78%	-14.35%	+3.93%	-4.64%
XERS Xeris Biopharma	0.00%	+4.21%	-4.67%	-14.39%	+108.89%
ZYBT Zhengye Biotechnology	0.00%	-28.92%	-28.77%	+22.86%	+660,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DNTH Dianthus Therapeutics	1.4329 of 5 stars	3.6	0.0	0.0	0.0	2.7	0.8	0.0
IPHA Innate Pharma	3.2376 of 5 stars	3.8	5.0	0.0	0.0	2.7	1.7	0.0
XERS Xeris Biopharma	4.1697 of 5 stars	3.4	1.0	0.0	4.2	3.4	2.5	0.6
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNTH Dianthus Therapeutics	3.14	Buy	$53.00	200.62% Upside
IPHA Innate Pharma	3.50	Strong Buy	$11.00	494.59% Upside
XERS Xeris Biopharma	2.83	Moderate Buy	$6.25	32.98% Upside
ZYBT Zhengye Biotechnology	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest IPHA, XERS, DNTH, and ZYBT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/13/2025	DNTH Dianthus Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$58.00 ➝ $50.00
5/13/2025	DNTH Dianthus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
5/9/2025	XERS Xeris Biopharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$6.00 ➝ $7.00
4/24/2025	IPHA Innate Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.50 ➝ $11.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNTH Dianthus Therapeutics	$6.24M	90.86	N/A	N/A	$11.91 per share	1.48
IPHA Innate Pharma	$21.77M	7.83	N/A	N/A	$0.11 per share	16.82
XERS Xeris Biopharma	$203.07M	3.62	N/A	N/A	($0.20) per share	-23.50
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNTH Dianthus Therapeutics	-$84.97M	-$2.88	N/A	N/A	N/A	-1,544.23%	-29.26%	-27.87%	8/6/2025 (Estimated)
IPHA Innate Pharma	-$53.53M	N/A	0.00	∞	N/A	N/A	N/A	N/A	9/17/2025 (Estimated)
XERS Xeris Biopharma	-$54.84M	-$0.30	N/A	N/A	N/A	-20.25%	N/A	-12.07%	8/6/2025 (Estimated)
ZYBT Zhengye Biotechnology	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest IPHA, XERS, DNTH, and ZYBT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/12/2025	Q1 2025	DNTH Dianthus Therapeutics	-$0.86	-$0.82	+$0.04	-$0.82	$0.81 million	$1.16 million
5/8/2025	Q1 2025	XERS Xeris Biopharma	-$0.07	-$0.06	+$0.01	-$0.06	$57.61 million	$57.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	N/A	N/A	N/A	N/A	N/A
XERS Xeris Biopharma	N/A	N/A	N/A	N/A	N/A
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNTH Dianthus Therapeutics	N/A	15.98	15.99
IPHA Innate Pharma	2.52	2.60	2.60
XERS Xeris Biopharma	N/A	1.72	1.17
ZYBT Zhengye Biotechnology	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNTH Dianthus Therapeutics	47.53%
IPHA Innate Pharma	0.16%
XERS Xeris Biopharma	42.75%
ZYBT Zhengye Biotechnology	N/A

Insider Ownership

Company	Insider Ownership
DNTH Dianthus Therapeutics	16.56%
IPHA Innate Pharma	31.89%
XERS Xeris Biopharma	4.56%
ZYBT Zhengye Biotechnology	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNTH Dianthus Therapeutics	80	32.16 million	26.83 million	Optionable
IPHA Innate Pharma	220	92.18 million	62.78 million	Not Optionable
XERS Xeris Biopharma	290	156.38 million	149.25 million	Optionable
ZYBT Zhengye Biotechnology	278	47.17 million	N/A	N/A

IPHA, XERS, DNTH, and ZYBT Headlines

Recent News About These Companies

Zhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) Lock-Up Period Will End on July 7th

14 minutes ago | marketbeat.com

ZYBT - Zhengye Biotechnology Holding Ltd Chart - Morningstar

June 27 at 8:34 PM | morningstar.comM

Zhengye Biotechnology Holding Ltd

June 21, 2025 | morningstar.comM

Zhengye Biotechnology (NASDAQ:ZYBT) Trading Down 6% - Time to Sell?

June 7, 2025 | marketbeat.com

ZYBT Zhengye Biotechnology Holding Limited

May 30, 2025 | seekingalpha.com

Zhengye Biotechnology faces NASDAQ compliance issue

May 24, 2025 | investing.com

Zhengye Biotechnology Holding Limited Receives NASDAQ Delinquency Letter for Non-Compliance with Listing Requirements

May 23, 2025 | quiverquant.comQ

Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F

May 23, 2025 | globenewswire.com

Should We Be Cautious About Zhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) ROE Of 6.9%?

April 7, 2025 | finance.yahoo.com

Zhengye Biotechnology Holding Ltd.

April 3, 2025 | wsj.com

Zhengye Biotechnology Holding Limited (ZYBT)

March 27, 2025 | finance.yahoo.com

Zhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment Option

January 14, 2025 | globenewswire.com

Zhengye Biotechnology Holding Limited Announces Closing of Initial Public Offering

January 8, 2025 | globenewswire.com

Zhengye Biotechnology Holding Limited Announces Pricing of Initial Public Offering

January 6, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA, XERS, DNTH, and ZYBT Company Descriptions

Dianthus Therapeutics NASDAQ:DNTH

$17.63 -0.50 (-2.76%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$17.68 +0.05 (+0.26%)

As of 06/27/2025 04:34 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Innate Pharma NASDAQ:IPHA

$1.84 -0.07 (-3.40%)

As of 06/27/2025 04:00 PM Eastern

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Xeris Biopharma NASDAQ:XERS

$4.70 -0.04 (-0.84%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.68 -0.02 (-0.43%)

As of 06/27/2025 07:46 PM Eastern

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Zhengye Biotechnology NASDAQ:ZYBT

$6.61 -0.44 (-6.24%)

As of 06/27/2025 04:00 PM Eastern

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time